Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Analytikerkommentar

Nightingale explores transfer to Nasdaq Helsinki main list and OTC trading in the US

Af Antti LuiroHead of Nordic ER Development, Analyst
Nightingale Health

Translation: Original published in Finnish on 11/27/2024 at 3:45 pm EET.

With the possible transfer and OTC cross-trading, the company aims, among other things, to improve the liquidity of the stock and to broaden its international shareholder base. As Nightingale has already made the transition to IFRS, we expect the transition to the main list to be a relatively straightforward process. The company expects the transition to occur in the first half of 2025, and given the press release, we believe it is highly likely.

List transfer and trading in the US can help build international business

Nightingale announced that its Board of Directors has decided to investigate the possibility of transferring its series B shares to the main list of Nasdaq Helsinki and possible cross-trading on the OTC market in the United States. With the planned move, the company aims, among other things, to improve the liquidity of the stock and expand its international shareholder base. Nightingale moved its reporting to IFRS already in 2022, which we see as a step towards strengthening the company's credibility with international clients and investors. The announcement of the transfer to the Nasdaq Helsinki main list and the entry to the US OTCQX market continues along this line.

Nightingale has entered a wide range of international partnerships, many of which have been in the US, so we do not think it is far-fetched to expect investor interest in the US market. On the other hand, being tradeable on the local market can increase the company's credibility among its existing and potential new local partners. Nightingale is well capitalized and will not consider issuing new shares in connection with the proposed move.

OTC Markets operates an exchange in the United States for securities not listed on a national exchange in the United States. According to Nightingale, the OTC market reaches US investors and has the advantage that entry into the OTC market is a simple and cost-effective process. The OTCQX is the highest quality tier of OTC Markets.

Of course, the move has no impact on the fair value of the company or our view of the stock, although the increased liquidity that the move would provide would in principle enhance the price formation of the company's stock.

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Læs mere på virksomhedsside

Key Estimate Figures23.09.2024

202425e26e
Omsætning4,46,510,8
vækst-%4,2 %50,1 %65,1 %
EBIT (adj.)-18,6-17,9-15,5
EBIT-% (adj.)-426,6 %-273,5 %-143,2 %
EPS (adj.)-0,29-0,28-0,23
Udbytte0,000,000,00
Udbytte %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forumopdateringer

Her er Antti & Anttis kommentarer til ændringerne i Nightingales ledelsesteam. Nightingale Health meddelte fredag, at de fornyer sammensætningen...
for 3 timer siden
af Sijoittaja-alokas
3
For et par måneder siden overvejede jeg, at virksomhedens bestyrelse er meget hjemmelavet til en global vækstfase, og sandelig er ledelsesgruppen...
12.12.2025, 13.49
af Puutaheinää
7
Pokker. Jeg har en fornemmelse af, at Barrett forlader af egen fri vilje. Han er den eneste person i virksomhedens ledelse, der har formået ...
12.12.2025, 13.40
af omegaalpha
9
Nightingale Health Oyj | Børsmeddelelse | 12.12.2025 kl. 14:55:00 EET Med udvidelsen af den internationale tilgængelighed af Nightingale Health...
12.12.2025, 13.21
af TO
2
Meget gode tal for det nye produkt! Herfra er det godt at fortsætte, og det var netop, hvad TT også tænkte, da de uddybede samarbejdet.
11.12.2025, 08.34
af Ossi
0
Én slide fra Jeffrey Barretts præsentation om UK Biobank. En stikprøve på 266 Terveystalo-ansatte viser i hvert fald, at testen er nyttig i ...
10.12.2025, 19.17
af Monsieur
16
Paavolas LinkedIn-opslag lyder ikke som om, de næste skridt er klare på nuværende tidspunkt: As announced yesterday, after four great years ...
9.12.2025, 18.57
af KuinVain
4
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.